Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822972 · ClinicalTrials.gov registry record · Phase 2
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
A Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06822972: Recruiting Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Duke University.
NCT06822972 is a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory that is actively recruiting participants, run by Duke University. The registered enrollment target is 27 participants, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06822972, a Phase 2 study of Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy. The investigators will enroll 27 patients with RRMM who are receiving commercial bispecific antibody therapy. Patients will be on treatment for 12 months or until disease progression, and will be followed for 24 months. Study assessments include completing a drug diary, having a safety check in call, and have history, clinical assessments, and labs taken. Twenty-seven patients will provide 80% power in a one-sample chi square test for a proportion assuming that the rate of negative MRD at 10-5 at 12 months post bispecific antibody therapy is 25% in historical control and 50% in the SEL+bispecific antibody experimental treatment group, under a one-sided 5% significance level.
Primary Outcome
Adverse events are defined using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Conditions Studied
Interventions
- DRUG Selinexor 40 mg
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-08-22 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06822972 shows while recruiting
NCT06822972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 49-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 1 intervention - of which Selinexor 40 mg is the first listed.
NCT06822972 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06822972 about?
NCT06822972 is a clinical study titled "HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM". The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD negativity rate at 10-5 at 12 months post bispecific antibody therapy. T...
What is the current status of trial NCT06822972?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-08-22. Estimated completion is 2027-12-31.
What conditions does trial NCT06822972 study?
This clinical trial studies the following conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory.
What interventions are being tested in trial NCT06822972?
The interventions under investigation include: Selinexor 40 mg (DRUG).
Who is sponsoring clinical trial NCT06822972?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06822972 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma in Relapse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06822972's enrollment target sits among peer trials
27 8th of 12 higher than 5 of 12 other Multiple Myeloma in Relapse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma in Relapse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI